BACKGROUND: Cystic fibrosis (CF) is a life-threatening disease affecting about 1:3000 newborns in Caucasian populations. The introduction of newborn screening for cystic fibrosis (CF NBS) has improved the clinical outcomes of individuals with CF through early diagnosis and early treatment. NBS strategies have been implemented over time. CF NBS was introduced extensively in 1984 in Tuscany, a region with 3.7 million people, characterized by a high allelic heterogeneity of CFTR gene. AIM AND METHODS: The aim of the study is to present the results from 34 years (1984-2018) of CF NBS, retrospectively evaluating the sensitivity, specificity and predictive values of the tests. In particular, we studied the impact of the introduction of DNA molecular analysis in NBS in a region with high allelic heterogeneity, such as Tuscany. RESULTS: Over these 34 years, 919,520 neonates were screened, using four different NBS strategies. From 1984 to 1991, CF NBS was performed by the determination of albumin on dried meconium (sensitivity 68.75%; specificity 99.82%). Subsequently, the analysis of immunoreactive trypsinogen on a blood spot was adopted as CF NBS protocol (sensitivity 83.33%; specificity 99.77%). From 1992 to 2010, this strategy was associated with lactase meconium dosage: IRT1/IRT2 + LACT protocol (sensitivity 87.50%; specificity 99.82%). From 2011, when the existing algorithm was integrated by analysis of CF causing variants of the CFTR gene (IRT1/IRT2 + LACT + IRT1/DNA protocol), a substantial improvement in sensitivity was seen (senisitivity 96.15%; specificity 99.75%). Other improved parameters with DNA analysis in the NBS programme, compared with the previous method, were the diagnosis time (52 days vs. 38 days) and the recall rate (0.58 to 0.38%). CONCLUSION: The inclusion of DNA analysis in the NBS was a fundamental step in improving sensitivity, even in a region with high allelic variability.
BACKGROUND:Cystic fibrosis (CF) is a life-threatening disease affecting about 1:3000 newborns in Caucasian populations. The introduction of newborn screening for cystic fibrosis (CF NBS) has improved the clinical outcomes of individuals with CF through early diagnosis and early treatment. NBS strategies have been implemented over time. CF NBS was introduced extensively in 1984 in Tuscany, a region with 3.7 million people, characterized by a high allelic heterogeneity of CFTR gene. AIM AND METHODS: The aim of the study is to present the results from 34 years (1984-2018) of CF NBS, retrospectively evaluating the sensitivity, specificity and predictive values of the tests. In particular, we studied the impact of the introduction of DNA molecular analysis in NBS in a region with high allelic heterogeneity, such as Tuscany. RESULTS: Over these 34 years, 919,520 neonates were screened, using four different NBS strategies. From 1984 to 1991, CF NBS was performed by the determination of albumin on dried meconium (sensitivity 68.75%; specificity 99.82%). Subsequently, the analysis of immunoreactive trypsinogen on a blood spot was adopted as CF NBS protocol (sensitivity 83.33%; specificity 99.77%). From 1992 to 2010, this strategy was associated with lactase meconium dosage: IRT1/IRT2 + LACT protocol (sensitivity 87.50%; specificity 99.82%). From 2011, when the existing algorithm was integrated by analysis of CF causing variants of the CFTR gene (IRT1/IRT2 + LACT + IRT1/DNA protocol), a substantial improvement in sensitivity was seen (senisitivity 96.15%; specificity 99.75%). Other improved parameters with DNA analysis in the NBS programme, compared with the previous method, were the diagnosis time (52 days vs. 38 days) and the recall rate (0.58 to 0.38%). CONCLUSION: The inclusion of DNA analysis in the NBS was a fundamental step in improving sensitivity, even in a region with high allelic variability.
Entities:
Keywords:
CFTR allelic heterogeneity; Cystic fibrosis; DNA molecular analysis; Immunoreactive trypsinogen; Newborn screening for cystic fibrosis CF NBS
Authors: Kelli K Ryckman; Stanton L Berberich; Oleg A Shchelochkov; Daniel E Cook; Jeffrey C Murray Journal: Clin Biochem Date: 2012-09-23 Impact factor: 3.281
Authors: A Tluczek; E H Mischler; P M Farrell; N Fost; N M Peterson; P Carey; W T Bruns; C McCarthy Journal: J Dev Behav Pediatr Date: 1992-06 Impact factor: 2.225
Authors: Clement L Ren; Drucy S Borowitz; Tanja Gonska; Michelle S Howenstine; Hara Levy; John Massie; Carlos Milla; Anne Munck; Kevin W Southern Journal: J Pediatr Date: 2017-02 Impact factor: 4.406
Authors: Philip M Farrell; Terry B White; Michelle S Howenstine; Anne Munck; Richard B Parad; Margaret Rosenfeld; Olaf Sommerburg; Frank J Accurso; Jane C Davies; Michael J Rock; Don B Sanders; Michael Wilschanski; Isabelle Sermet-Gaudelus; Hannah Blau; Silvia Gartner; Susanna A McColley Journal: J Pediatr Date: 2017-02 Impact factor: 4.406
Authors: Molly Kloosterboer; Gary Hoffman; Michael Rock; William Gershan; Anita Laxova; Zhanhai Li; Philip M Farrell Journal: Pediatrics Date: 2009-02 Impact factor: 7.124